Connect your AI

Evommune EVMN Line Of Credit Facility Periodic Payment Principal

Line Of Credit Facility Periodic Payment Principal at other companies

TrupanionTRUP

0.3%0.0pp

Employers HoldingsEIG

$50K+100%

Two Harbors Investment CorporationTWO

$54.22M+135%

Medline, Inc. MDLN

$0-100%

ARD

Ardent Health PartnersARDT

$0—

CarMaxKMX

$1.67B+1,736%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's line of credit facility periodic payment principal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's line of credit facility periodic payment principal?: Evommune (EVMN) reported line of credit facility periodic payment principal of $845.25 in Q4 2025.
What does line of credit facility periodic payment principal mean?: The periodic cash payments made toward the principal balance of a revolving line of credit or similar short-term debt facility. Monitoring these payments helps assess the company's ability to manage and reduce its short-term debt burden.